



Research Article

A FACILE AND AN EFFICIENT SYNTHESIS OF 3, 3-DISUBSTITUTED OXINDOLE SCAFFOLDS AND THEIR CYTOTOXIC PROPERTIES

Sasikala Maadwar^{1,2*}, Rajitha Galla¹, Santhosh K. G^{1,2}

¹Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati, India

²Medicinal Chemistry and Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad, India

*Corresponding Author Email: maadwarsasikala@gmail.com

Article Received on: 13/02/19 Approved for publication: 02/04/19

DOI: 10.7897/2230-8407.1004148

ABSTRACT

3,3-disubstituted oxindole derivatives were synthesised by treating isatins with electron rich benzene derivatives at room temperature by using $\text{BF}_3\text{O}(\text{Et})_2$ as catalyst which reduced the synthesis time. The compounds were evaluated for cytotoxic activity against human breast cancer cells (MCF7) and human ovarian carcinoma cells (SKVO3) by using MTT assay. Compounds **1** ($7.2 \pm 0.22 \mu\text{M}$ and $11.80.21 \pm \mu\text{M}$), **2** ($7.10.24 \pm \mu\text{M}$ and $9.8 \pm 0.27 \mu\text{M}$), exhibited relatively higher cytotoxic activity against both MCF7 and SKVO3 cell lines, respectively.

Keywords: Isatins, Methoxy Benzenes, Boron Trifluoride Diethyl Etherate, MCF7 and SKVO3

INTRODUCTION

Cancer is characterised by a change in controlled mechanisms that manage cell proliferation, differentiation and is continuing to be a major health problem in developing as well as undeveloped countries. Malignancy is caused by abnormalities in cells, which might be due to inherited genes or caused by exogenous agents including chemicals, radiation and some infectious agents¹.

Organic compounds with an oxindole framework are represented in a large family of a pharmaceutically active compounds and bioactive natural products. Particularly, spirooxindole and 3, 3-disubstituted derivatives were present in a number of alkaloids which possess significant biological activities. Such as anticancer², antidepressant³, anticonvulsant⁴, antifungal⁵, anti-HIV⁶, anti-inflammatory⁷. During past decades, researchers have embarked on the development of new oxindole based anticancer agents⁸⁻¹⁰. 5-fluoro-3-substituted-2-oxindole derivative compound SU11248 [Sutent] received FDA approval for the treatment of gastrointestinal stromal tumors and advanced renal cell carcinoma¹¹. Due to the importance of oxindole motifs, several methods have been developed for the construction such structural motifs¹²⁻¹⁹. Despite of effectiveness, these methods involve use of expensive catalysts²⁰⁻²², long reaction time^{16,17,19,23}, tedious work up, vigorous reaction conditions¹⁵ and poor yield¹⁹. Therefore there is need to develop efficient, convenient and practical protocol to synthesize oxindole scaffolds.

In the present investigation, we have developed a rapid and efficient method for synthesis of methoxy benzene substituted oxindoles using boron trifluoride diethyl etherate as catalyst. The newly synthesized 3,3-disubstituted oxindole are evaluated for their cytotoxic potentials against wild type human breast cancer cell line (MCF7) and human ovarian carcinoma cells (SKVO3).

MATERIALS AND METHODS

Chemistry

All the starting materials procured from Sigma Aldrich and used without further purification. Solvents were of analytical grade. All the reactions were carried out with the use of standard techniques and were monitored by analytical TLC performed on pre-coated silica.

General procedure for synthesis of 3,3-disubstituted oxindoles

To 1.0 equivalent of isatin 1.5 equivalent of tri and di methoxy benzene was added in DCM in a RBF, stirred it for 2min, 0.2ml of $[\text{BF}_3\text{O}(\text{Et})_2]$ was added and stirred it for another 5-10 min (**Scheme 1**). Reaction was monitored by TLC, excess of reagent was quenched with solid sodium bicarbonate and directly loaded on to column. The structure of the compounds were confirmed by ¹H NMR, ¹³CNMR, IR and Mass-spectroscopy. Elemental analysis: Calculated: C, 70.71; H,5.34; N,8.25, Found : C,70.72; H,5.31; N,8.27

5-chloro-3,3-bis(2,4,6-trimethoxyphenyl)indolin-2-one (1):

Light red solid; Mp 180-182°C; ¹H NMR (300 MHz, CDCl_3): δ 3.54 (s, 3H), 3.68 (s, 3H), 6.72 (s, 3H), 3.80 (s, 3H), 3.85 (s, 3H), 3.88 (s, 3H), 5.14 (s, 1H), 6.09 (dd, $J = 2.13$ Hz and 8.39 Hz, 1H), 6.20 (dd, $J = 2.13$ Hz and 5.95 Hz, 2H), 6.22 (d, $J = 2.28$ Hz, 1H), 6.74 (s, 1H), 7.00 (s, 1H), 8.68 (br s, 1H) ppm. ¹³CNMR (75 MHz, CDCl_3): δ 842.5, 55.2, 55.3, 55.7, 55.9, 89.6, 89.8, 90.6, 90.8, 91.6, 105.7, 108.7, 109.9, 113.2, 124.3, 127.1, 128.0, 131.0, 132.3, 139.8, 158.2, 158.3, 158.8, 159.3, 161.0, 180.1 ppm. IR (KBr): $\nu = 809, 1116, 1153, 1225, 1458, 1609, 1707, 2936$ cm^{-1} . MS-ESI: $m/z = 500$ $[\text{M}+\text{H}]^+$, 522 $[\text{M}+\text{Na}]^+$. Elemental analysis: Calculated: C,62.46; H,5.24; Cl,7.09; O,22.40, Found : C,62.44; H,5.23; Cl,7.08; O,22.40.

5-bromo-3,3-bis(2,4,6-trimethoxyphenyl)indolin-2-one (2):

Light red solid; Mp 233-235 °C; ¹H NMR (300 MHz, CDCl₃): δ 3.56 (s, 3H), 3.69 (s, 3H), 3.73 (s, 3H), 3.81 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 5.14 (s, 1H), 6.08 (d, *J* = 6.02 Hz, 1H), 6.19-6.23 (m, 3H), 6.73 (s, 1H), 7.18 (s, 1H), 8.01 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 42.3, 55.3, 55.7, 55.9, 90.6, 90.7, 91.6, 111.9, 112.9, 127.4, 131.3, 134.5, 140.4, 158.1, 159.3, 161.0, 179.4 ppm. IR (KBr): ν = 782, 818, 1029, 1155, 1267, 1456, 1521, 1735, 3291 cm⁻¹. MS-ESI: *m/z* = 544 [M]⁺. Elemental analysis: Calculated: C, 57.36; H, 4.81; Br, 14.68; N, 2.57; O, 20.57. Found: C, 57.37; H, 4.83; Br, 14.69; N, 2.56; O, 20.59.

3,3-bis(2,4-dimethoxyphenyl)indolin-2-one (3):

Light yellow solid; Mp 180-182 °C; ¹H NMR (300 MHz, CDCl₃): δ 3.46 (s, 3H), 3.63 (s, 3H), 3.77 (s, 6H), 6.36 (d, *J* = 8.39 Hz, 1H), 6.40-6.48 (m, 3H), 6.81 (t, *J* = 7.78 Hz, 2H), 6.88 (td, *J* = 0.91 Hz and 7.62 Hz, 1H), 7.11 (td, *J* = 1.06 Hz and 7.62 Hz, 1H), 7.21 (d, *J* = 7.93 Hz, 2H), 8.25 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 55.1, 55.2, 55.6, 59.2, 99.7, 100.1, 104.1, 104.2, 108.8, 120.2, 120.5, 121.6, 125.2, 127.1, 125.5, 127.1, 129.6, 130.8, 135.3, 140.6, 158.5, 158.9, 160.0, 180.9 ppm. IR (KBr): ν = 760, 1035, 1134, 1210, 1310, 1468, 1609, 1709 cm⁻¹. MS-ESI: *m/z* = 406 [M+H]⁺, 428 [M+Na]⁺. Elemental analysis: Calculated: C, 71.10; H, 5.72; N, 3.45; O, 19.73. Found: C, 71.12; H, 5.74; N, 3.44; O, 19.75.

5-chloro-3,3-bis(2,4-dimethoxyphenyl)indolin-2-one (4):

Light yellow solid; Mp 152-154 °C; ¹H NMR (300 MHz, CDCl₃): δ 3.43 (s, 3H), 3.67 (s, 3H), 3.77 (s, 6H), 6.36-6.51 (m, 4H), 6.72 (d, *J* = 8.24 Hz, 1H), 6.81 (d, *J* = 8.54 Hz, 1H), 7.01 (dd, *J* = 2.13 and 8.24 Hz, 1H), 7.23 (d, *J* = 8.54 Hz, 1H), 7.27 (d, *J* = 1.98 Hz, 1H), 8.61 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 55.0, 55.2, 55.5, 59.6, 99.8, 104.2, 104.4, 109.7, 118.9, 119.7, 125.8, 126.8, 129.6, 130.9, 137.2, 139.3, 158.4, 158.6, 160.3, 180.9 ppm. IR (KBr): ν = 819, 1030, 1208, 1306, 1465, 1504, 1610, 1713, 2934 cm⁻¹. MS-ESI: *m/z* = 440 [M+H]⁺, 462 [M+Na]⁺. Elemental analysis: Calculated: C, 65.53; H, 5.04; Cl, 8.06; N, 3.18; O, 18.19. Found: C, 65.53; H, 5.06; Cl, 8.08; N, 3.17; O, 18.17.

5-bromo-3,3-bis(2,4-dimethoxyphenyl)indolin-2-one (5):

White solid; Mp 202-204 °C; ¹H NMR (300 MHz, CDCl₃): δ 3.43 (s, 3H), 3.68 (s, 3H), 3.77 (s, 6H), 6.38 (d, *J* = 8.69 Hz, 1H), 6.44 (d, *J* = 9.15 Hz, 2H), 6.48 (s, 1H), 6.81 (d, *J* = 8.69 Hz, 1H), 7.21 (dd, *J* = 1.98 Hz, *J* = 8.24 Hz, 2H), 7.24 (d, *J* = 8.54 Hz, 1H), 7.41 (d, *J* = 1.98 Hz, 1H), 8.62 (s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 54.9, 55.3, 55.5, 59.6, 99.8, 104.2, 110.3, 114.3, 128.6, 129.7, 131.0, 137.6, 139.8, 158.4, 158.6, 160.3, 180.7 ppm. IR (KBr): ν = 768, 812, 1021, 1144, 1263, 1451, 1515, 1724, 3288 cm⁻¹. MS-ESI: *m/z* = 484 [M+H]⁺, 506 [M+Na]⁺. Elemental analysis: Calculated: C, 59.52; H, 4.58; Br, 16.50; N, 2.89; O, 16.52. Found: C, 59.54; H, 4.59; Br, 16.50; N, 2.87; O, 16.54.

3, 3-bis(2,4-dimethoxyphenyl)-5-methoxyindolin-2-one (6):

White solid; Mp 110-112 °C; ¹H NMR (300 MHz, CDCl₃): δ 3.46 (s, 3H), 3.66 (s, 3H), 3.68 (s, 3H), 3.77 (s, 6H), 6.36 (d, *J* = 8.69 Hz, 1H), 6.43 (d, *J* = 8.54 Hz, 2H), 6.46 (s, 1H), 6.65 (dd, *J* = 2.59 Hz, *J* = 8.39 Hz, 1H), 6.72 (d, *J* = 8.39 Hz, 1H), 6.82 (d, *J* = 8.54 Hz, 1H), 6.90 (d, *J* = 2.44 Hz, 1H), 7.21 (d, *J* = 8.69 Hz, 1H), 8.16 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 55.1, 55.2, 55.6, 59.8, 99.7, 100.0, 104.1, 104.3, 108.8, 111.5, 112.8, 120.1, 120.5, 129.6, 130.8, 134.3, 136.9, 155.1, 158.5, 158.8, 160.0, 160.1, 180.7 ppm. IR (KBr): ν = 731, 823, 1040, 1215, 1519, 1721, 3192 cm⁻¹. MS-ESI: *m/z* = 436 [M+H]⁺. Elemental analysis: Calculated: C, 68.95; H, 5.79; N, 3.22; O, 22.04. Found: C, 68.97; H, 5.77; N, 3.23; O, 22.06.

3,3-bis(2,4-dimethoxyphenyl)-5-methylindolin-2-one (7):

Light yellow solid; Mp 177-179 °C; ¹H NMR (300 MHz, CDCl₃):

δ 2.21 (s, 3H), 3.48 (s, 3H), 3.63 (s, 3H), 3.77 (s, 6H), 6.36 (d, *J* = 8.39 Hz, 1H), 6.43 (d, *J* = 8.54 Hz, 1H), 6.45 (d, *J* = 2.44 Hz, 2H), 6.70 (d, *J* = 7.78 Hz, 1H), 6.79 (d, *J* = 8.69 Hz, 1H), 6.92 (d, *J* = 8.69 Hz, 1H), 6.98 (s, 1H), 7.17 (d, *J* = 8.54 Hz, 1H), 8.16 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 21.2, 55.1, 55.2, 55.7, 59.2, 99.7, 100.2, 104.1, 104.3, 108.5, 120.5, 120.7, 126.3, 127.4, 129.6, 130.7, 130.8, 135.1, 138.2, 158.4, 159.1, 159.8, 160.1, 180.8 ppm. IR (KBr): ν = 727, 801, 1027, 1206, 1501, 1703, 3178 cm⁻¹. MS-ESI: *m/z* = 420 [M+H]⁺. Elemental analysis: Calculated: C, 71.58; H, 6.01; N, 3.34; O, 19.07. Found: C, 71.59; H, 6.03; N, 3.36; O, 19.08.

3,3-bis(3,4-dimethoxyphenyl)indolin-2-one (8):

White solid; Mp 178-180 °C; ¹H NMR (300 MHz, CDCl₃): δ 3.75 (s, 6H), 3.84 (s, 6H), 6.77 (d, *J* = 7.17 Hz, 4H), 6.85 (s, 2H), 6.96 (br d, *J* = 7.78 Hz, 1H), 7.06 (td, *J* = 0.96 Hz, *J* = 7.62 Hz, 1H), 7.20 (br d, *J* = 7.17 Hz, 1H), 7.24 (td, *J* = 1.22 Hz, *J* = 7.78 Hz, 1H), 8.38 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 55.8, 55.9, 62.0, 110.1, 110.6, 111.9, 120.6, 122.7, 126.1, 128.1, 133.8, 139.8, 148.3, 148.7, 180.0 ppm. IR (KBr): ν = 760, 1018, 1153, 1258, 1514, 1614, 1716, 3294 cm⁻¹. MS-ESI: *m/z* = 406 [M+H]⁺, 428 [M+Na]⁺. Elemental analysis: Calculated: C, 71.10; H, 5.72; N, 3.45; O, 19.73. Found: C, 71.10; H, 5.74; N, 3.44; O, 19.75.

5-chloro-3,3-bis(3,4-dimethoxyphenyl)indolin-2-one (9):

Light yellow solid; Mp 185-187 °C; ¹H NMR (300 MHz, CDCl₃): δ 3.76 (s, 6H), 3.85 (s, 6H), 6.73 (dd, *J* = 2.13 and *J* = 8.39 Hz, 2H), 6.78 (d, *J* = 8.39 Hz, 2H), 6.83 (d, *J* = 1.98 Hz, 2H), 6.89 (d, *J* = 8.24 Hz, 1H), 7.15 (d, *J* = 1.98 Hz, 1H), 7.21 (dd, *J* = 1.98 Hz, *J* = 8.24 Hz, 1H), 8.98 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 55.8, 55.9, 62.3, 110.7, 111.3, 111.8, 120.4, 126.3, 128.0, 128.2, 133.0, 135.6, 138.5, 148.6, 148.9, 180.0 ppm. IR (KBr): ν = 821, 1027, 1221, 1315, 1470, 1521, 1623, 1715, 2951 cm⁻¹. MS-ESI: *m/z* = 440 [M+H]⁺. Elemental analysis: Calculated: C, 65.53; H, 5.04; Cl, 8.06; N, 3.18; O, 18.19. Found: C, 65.55; H, 5.07; Cl, 8.08; N, 3.19; O, 18.17.

5-bromo-3,3-bis(3,4-dimethoxyphenyl)indolin-2-one (10):

White solid; Mp 181-183 °C; ¹H NMR (300 MHz, CDCl₃): δ 3.76 (s, 6H), 3.85 (s, 6H), 6.73 (dd, *J* = 2.13 Hz, *J* = 8.39 Hz, 2H), 6.79 (d, *J* = 8.39 Hz, 2H), 6.83 (d, *J* = 2.13 Hz, 2H), 6.85 (s, 1H), 7.28 (d, *J* = 1.98 Hz, 1H), 7.36 (dd, *J* = 1.98 Hz, *J* = 8.24 Hz, 1H), 8.91 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 55.8, 55.9, 62.2, 110.7, 111.8, 115.3, 120.4, 129.1, 131.1, 133.0, 135.9, 139.0, 148.6, 148.9, 179.9 ppm. IR (KBr): ν = 765, 810, 1022, 1140, 1262, 1465, 1513, 1721, 3280 cm⁻¹. MS-ESI: *m/z* = 483 [M]⁺, 485 [M+2H]⁺. Elemental analysis: Calculated: C, 59.52; H, 4.58; Br, 16.50; N, 2.89; O, 16.52. Found: C, 59.54; H, 4.59; Br, 16.51; N, 2.87; O, 16.54.

3,3-bis(3,4-dimethoxyphenyl)-5-methoxyindolin-2-one (11):

Yellow solid; Mp 180-182 °C; ¹H NMR (300 MHz, CDCl₃): δ 3.74 (s, 3H), 3.76 (s, 6H), 3.85 (s, 6H), 6.77 (s, 6H), 6.85 (s, 3H), 8.19 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 55.7, 55.8, 55.9, 62.4, 110.4, 110.7, 112.0, 112.6, 113.3, 120.6, 113.2, 113.8, 135.3, 148.4, 148.8, 155.8, 179.8 ppm. IR (KBr): ν = 721, 810, 1032, 1212, 1502, 1713, 3181 cm⁻¹. MS-ESI: *m/z* = 436 [M+H]⁺. Elemental analysis: Calculated: C, 68.95; H, 5.79; N, 3.22; O, 22.04. Found: C, 68.97; H, 5.77; N, 3.23; O, 22.06.

3,3-bis(3,4-dimethoxyphenyl)-5-methylindolin-2-one (12):

Light yellow solid; Mp 170-172 °C; ¹H NMR (300 MHz, CDCl₃): δ 2.30 (s, 3H), 3.76 (s, 6H), 3.85 (s, 6H), 6.74-6.79 (m, 4H), 6.83-6.87 (m, 3H), 6.98 (s, 1H), 7.03 (d, *J* = 7.78 Hz, 1H), 8.50 (br s, 1H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ 21.2, 55.7, 55.9, 62.1, 109.9, 110.6, 112.0, 120.6, 126.6, 128.5, 132.1, 133.9, 137.4, 148.3, 148.7, 180.2 ppm. IR (KBr): ν = 729, 804, 1031, 1201,

1505, 1716, 3181 cm^{-1} . MS-ESI: $m/z = 420$ $[\text{M}+\text{H}]^+$. Elemental analysis: Calculated: C, 71.58; H, 6.01; N, 3.34; O, 19.07, Found: C, 71.59; H, 6.03; N, 3.36; O, 19.09.

3,3-bis(2,5-dimethoxyphenyl)indolin-2-one (13): Light yellow solid; Mp 238-240 $^{\circ}\text{C}$; ^1H NMR (300 MHz, CDCl_3): δ 3.45 (s, 3H), 3.58 (s, 3H), 3.64 (s, 3H), 3.69 (s, 3H), 6.51 (d, $J = 2.74$ Hz, 1H), 6.75-6.79 (m, 2H), 6.80-6.86 (m, 3H), 6.87 (d, $J = 2.74$ Hz, 1H), 6.90 (t, $J = 7.62$ Hz, 1H), 7.13 (t, $J = 7.62$ Hz, 1H), 7.23 (d, $J = 7.47$ Hz, 1H), 7.99 (br s, 1H) ppm. ^{13}C NMR (75 MHz, CDCl_3): δ 55.5, 55.7, 56.0, 56.4, 60.1, 108.9, 112.5, 112.6, 113.3, 114.0, 115.6, 116.9, 121.9, 125.8, 127.5, 129.2, 129.4, 134.2, 140.7, 151.7, 152.5, 153.3, 153.6, 179.6 ppm. IR (KBr): $\nu = 772$, 1030, 1157, 1256, 1522, 1631, 1719, 3284 cm^{-1} . MS-ESI: $m/z = 406$ $[\text{M}+\text{H}]^+$. Elemental analysis: Calculated: C, 74.02; H, 5.95; N, 3.60; O, 16.43, Found: C, 74.04; H, 5.97; N, 3.62; O, 16.45.

3,3-bis(2,5-dimethoxyphenyl)-5-methoxyindolin-2-one (14): Brown solid; Mp 135-137 $^{\circ}\text{C}$; ^1H NMR (300 MHz, CDCl_3): δ 3.44 (s, 3H), 3.60 (s, 3H), 3.64 (s, 3H), 3.68 (s, 6H), 6.54 (d, $J = 2.74$ Hz, 1H), 6.66 (dd, $J = 2.59$ and 8.54 Hz, 1H), 6.73 (d, $J = 8.39$ Hz, 1H), 6.77 (d, $J = 8.85$ Hz, 2H), 6.82 (d, $J = 8.85$ Hz, 2H), 6.88 (d, $J = 2.59$ Hz, 1H), 6.92 (d, $J = 2.44$ Hz, 1H), 8.64 (br s, 1H) ppm. ^{13}C NMR (75 MHz, CDCl_3): δ 55.5, 55.9, 56.4, 60.3, 60.8, 109.2, 111.9, 112.5, 113.0, 113.2, 113.8, 114.5, 11.5, 116.9, 129.0, 129.4, 134.6, 135.7, 151.8, 152.4, 153.2, 153.6, 155.2, 180.0 ppm. IR (KBr): $\nu = 728$, 801, 1027, 1231, 1495, 1704, 3171 cm^{-1} . MS-ESI: $m/z = 436$ $[\text{M}+\text{H}]^+$, 458 $[\text{M}+\text{Na}]^+$. Elemental analysis: Calculated: C, 71.58; H, 6.01; N, 3.34; O, 19.07, Found: C, 71.59; H, 6.03; N, 3.36; O, 19.09.

3,3-bis(2,5-dimethoxyphenyl)-5-methylindolin-2-one (15): Brown solid; Mp 230-232 $^{\circ}\text{C}$; ^1H NMR (300 MHz, CDCl_3): δ 2.21 (s, 3H), 3.47 (s, 3H), 3.58 (s, 3H), 3.64 (s, 3H), 3.69 (s, 3H), 6.49 (d, $J = 2.74$ Hz, 1H), 6.71 (d, $J = 7.78$ Hz, 1H), 6.74-6.79 (m, 2H), 6.80-6.86 (m, 3H), 6.94 (br d, $J = 7.47$ Hz, 1H), 7.00 (br s, 1H), 7.91 (br s, 1H) ppm. ^{13}C NMR (75 MHz, CDCl_3): δ 21.2, 55.5, 55.7, 56.1, 56.5, 60.1, 108.6, 112.4, 113.4, 114.1, 115.5, 117.0, 126.6, 128.0, 129.6, 131.2, 134.0, 138.2, 151.6, 152.7, 153.2, 153.6, 179.6 ppm. IR (KBr): $\nu = 725$, 797, 1035, 1222, 1507, 1701, 3172 cm^{-1} . MS-ESI: $m/z = 420$ $[\text{M}+\text{H}]^+$. Elemental analysis: Calculated: C, 74.42; H, 6.25; N, 3.47; O, 15.86, Found: C, 74.44; H, 6.26; N, 3.49; O, 15.88.

In vitro Cytotoxic Activity of Novel 3,3-disubstituted oxindoles

Cell viability of the test compounds were determined on the basis of measurement of in vitro growth inhibition of cell lines by cell mediated reduction of tetrazolium salt to form water insoluble formazan crystals. The compounds were evaluated for cytotoxic activity against various cancer cell lines such as human breast cancer cells (MCF7) and human ovarian carcinoma cells (SKVO3) by using MTT assay²⁴. Briefly, the exponential growing cells were harvested and plated (1×10^4) in 96-well microtiter plates and grown for a period of 24 h. The cells were treated with different concentrations of test compounds and incubated for 48 h. Later, the cells were incubated again for 2 h with 250 $\mu\text{g mL}^{-1}$ of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). After incubation, the medium was replaced with 100 μL of DMSO and the absorbance was measured at 570 nm. The IC_{50} values of the compounds were calculated from the dose-response curves. Doxorubicin was used as a positive control for both cancer and normal cell lines. Each experiment was performed in triplicates and the IC_{50} values were expressed in mean \pm SD.

RESULTS AND DISCUSSION

Compounds were synthesised by reacting different substituted isatins with 1,3,5-trimethoxy benzenes, 1,3-dimethoxy benzenes, 1,2-dimethoxy benzenes and 1,4-dimethoxy benzenes using boron trifluoride diethyl etherate as catalyst. The completion of reaction was identified by TLC and all the compounds were purified by column chromatography and the synthesised compounds were confirmed by ^1H NMR, ^{13}C NMR, IR and Mass spectroscopy. In the ^1H NMR spectra of newly synthesised compounds, the secondary amine peak was found at the range of 7.91-8.98 ppm. All the methoxy protons were found at the range of 3.26-3.85 ppm as a characteristic singlet signal. All the remaining aromatic and aliphatic proton peaks were observed at their expected regions. ^{13}C NMR of all the compounds showed appropriate signals. Synthesised compounds were analysed by mass spectra under ESI, molecular ions were analysed in the form of $\text{M}+1$. The data indicates that as such there is no difference in the fragmentation pattern among the derivatives.

Formation of 3,3-disubstituted oxindole motif is a Lewis acid catalysed nucleophilic addition elimination type of reaction (Figure 1). In this reaction, carbonyl oxygen present on 3rd carbon of isatin molecule, donates an electron pair to Boron trifluoridodiethyletherate which generates an electron deficiency on third carbon atom of isatin. Due to this the electron rich tri or dimethoxy benzenes as a nucleophile attacks at that position of isatin, followed by regeneration and reattack of Lewis acid at hydroxyl oxygen which again forms an electropositive centre on that carbon (3rd position) which makes it possible for one more methoxy benzene to attack resulting in the formation of 3,3 disubstituted oxindoles.

In vitro Cytotoxic Activity

Novel 3,3-disubstituted oxindoles were evaluated for cytotoxicity against human breast cancer cells (MCF7) and human ovarian carcinoma cell lines (SKVO3) using MTT assay, with doxorubicin as standard. Results (Table 1) revealed that both MCF7 and SKVO3 cell lines were susceptible to the evaluated compounds. Compounds **1** and **2** showed good activity with IC_{50} Values 7.2 ± 0.22 , 7.1 ± 0.24 , μM respectively against MCF7 and 11.8 ± 0.21 , 9.8 ± 0.27 , μM respectively against SKVO3 cell lines, whereas, remaining all other compounds showed moderate activity against both cell lines.

1,3,5 trimethoxybenzene substituted isatins have showed good activity compared to dimethoxy benzene compounds which indicates the significance of additional methoxy group on benzene. Compounds **1** and **2** having chloro and bromo substitution respectively at 5th position showed good activity which may be due to negative inductive effect.

CONCLUSION

In the current investigation, a efficient method was developed for synthesis of a series of novel 3,3-disubstituted oxindoles using Boron trifluoride diethyl etherate as catalyst. This process is simple to operate, less time consuming with no work up and reaction conditions are mild. The newly developed di and tri substituted oxindole resulted in considerable cytotoxic activity against both human breast cancer cell lines (MCF7) and human ovarian carcinoma cell lines (SKVO3). Of the developed set of molecules, compound **1** and **2** exhibited relatively higher cytotoxic activity against both MCF7 and SKVO3 cell lines.

SCHEME









Figure 1: Probable Reaction Mechanism for the Formation of 3,3-Disubstituted Oxindole Scaffold

Table 1: *In Vitro* Cytotoxic Activity Of 3,3 disubstituted oxindoles By MTT Assay

Compound No.	R	IC ₅₀ values in (μM) ^a	
		MCF7 ^b	SKVO3 ^c
1	Cl	7.2±0.22	11.8±0.21
2	Br	7.1±0.24	9.8±0.27
3	H	18.6±0.34	16.8±0.32
4	Cl	29.5±0.29	11.0±0.29
5	Br	21.4±0.31	21.7±0.33
6	OMe	34.8±0.68	15.1±0.26
7	Me	40.8±0.57	35.2±0.41
8	H	15.6±0.42	17.8±0.12
9	Cl	11.1±0.44	12.4±0.42
10	Br	11.5±0.22	14.5±0.27
11	OMe	17.1±0.26	15.9±0.37
12	Me	18.1±0.23	11.8±0.61
13	H	14.5±0.57	16.6±0.21
14	OMe	15.1±0.67	18.2±0.49
15	Me	15.3±0.9	14.3±0.33
Doxorubicin		1.6±0.28	1.8±0.47

^a 50% cytotoxic concentration or compound concentration required to reduce viability of MCF7 or SKVO3 cell lines by 50%, using the MTT methodology, ^b Breast cancer cell lines,

^c Ovarian cancer cell lines, MCF7 breast cancer (ATCC® HTB22™), SKOV3 ovarian cancer (ATCC® HTB 77™)

ACKNOWLEDGEMENTS

The authors would like to thank Dr. Sunil Misra (Senior Scientist, Biology Division, CSIR-IICT, and Hyderabad) for providing biological laboratory facilities to perform biological evaluation. We also thank Mrs. Swetha and Mr. Devender, (Discovery Labs, CSIR-IICT, Hyderabad), for providing facilities to perform chemical reactions.

REFERENCES

- Naresh Kumar R, Poornachandra Y, Nagender Y, Santhosh Kumar G, Krishna Swaroop D, Ganesh Kumar, et al. Synthesis of novelnicotino-Hydarzide and (1,3,4-oxadiazole-2-yl)-6-(Trifluoro methyl)pyridine derivatives as potential Anticancer agents. *Bioorg Med Chem Lett* 2016; 26: 4829-4831.
- Ibrahim HS, Abou-seri SM, Tanc M, Elaasser MM, Abdel-Aziz HA, Supuran CT. Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII. *Eur J Med Chem* 2015; 103: 583-593.
- Rohini R, Reddy PM, Shanker K, Kanthaiiah K, Ravender V, Hu A. Synthesis of mono, bis-2-(2-arylideneaminophenyl) indole azomethines as potential antimicrobial agents. *Arch Pharm Res* 2011; 34: 1077-1084.
- Verma M, Pandeya SN, Singh KN, Stables JP. Anticonvulsant activity of Schiff bases of isatin derivatives. *Acta pharm* 2004; 54: 49-56.
- Pandeya SN, Yogeeshwari P, Sri Ram, Nath DG. Synthesis, antibacterial and antifungal activities of N-mannich bases of 3-[N2-pyrimethaminylimino] isatin. *Indian J Pharm Sci* 2002; 64: 209-212.
- Selvam P, Muruges N, Chandra mohan M, Debyser Z, Witvrouw M. Synthesis and antiHIV activity of Novel Isatin-Sulphonamides. *Indian J Pharm Sci* 2008; 70: 779-782.
- Sridhar SK, Ramesh. Synthesis and pharmacological activities of hydrazones, Schiff and Mannich bases of isatin derivatives. *Biol Pharm Bull* 2001; 24: 1149-1152.
- Eldehna WM, Altoukhy A, Maherous H, Abdel-Aziz HA. Design, synthesis and QSAR study of certain isatin-pyridine hybrids as potential anti-proliferative agents. *Eur J Med Chem* 2015; 90: 684-694.
- Sharma P, Senwar KR, Jeengar MK, Reddy TS, Naidu VG, Kamal A, Shankaraiah N. H₂O-mediated isatin spiroepoxide ring opening with NaCN: Synthesis of novel 3-tetrazolylmethyl-3-hydroxy-oxindole hybrids and their anticancer evaluation. *Eur J Med Chem* 2015; 104: 11-24.
- Pervez H, Ramzan M, Yaquub M, Khan KM. Cytotoxic and Phytotoxic Effects of Some New N4-Aryl Substituted Isatin-3-thiosemicarbazones. *Med Chem* 2012; 8: 505-514.
- Hamdy AM, Al-Masoudi NA, Pannecouque C, Rahman Q, Villinger A, Langer P. Regioselective synthesis Suzuki-Miyaura reaction of 4,7-dichloro-N-methylisatin. Synthesis, anti-HIV activity and modelling studies. *Rsc Adv* 2015; 5: 107360-107369.
- Bandgar BP, Shaikh AK. Molecular iodine catalyzed efficient and highly rapid synthesis of bis(indolyl) methanes under mild conditions. *Tetrahedron Lett* 2003; 44: 1959-1961.
- Bandgar BP, Bettigeri SA, Joshi NS. Hexamethylenetetramine-Bromine Catalysed Rapid and Efficient synthesis of bis(indolyl) methanes. *Monatshfte fur Chemie* 2004; 135: 1265-1273.
- Silveira CC, Mendes SR, Libero FM, Leonardao EJ, Perrin G. Glycerine and CeCl₃·7H₂O: A new and efficient recyclable medium for the synthesis of bis(indolyl) methanes. *Tetrahedron Lett* 2009; 50: 6060-6063.
- Xia M, Wang SB, Yuan WB. Lewis acid catalysed electrophilic substitution of indole with schiffs bases under microwave solvent free irradiation. *Synth Commun.* 2004; 34: 3175-3182.
- Babu G, Sridhar N, Perumal PT. A convenient method of synthesis of bis(indolyl)methanes: Indium trichloride catalysed reaction of indoles with aldehydes and schiffs bases. *Synth Commun* 2000; 30: 1609-1614.
- Bandgar BP, Shaikh KA. Organic reactions in aqueous media: In F3 catalysed synthesis of bis(indolyl)methanes in water under mild conditions. *J Chem Res Synop* 2004; 34: 72-74.
- Reddy YT, Reddy PN, Kumar BS, Rajitha B. Efficient synthesis of Bis(indolyl)methanes catalysed by TiCl₄. *Indian J Chem* 2005; 44B: 2393-2395.
- Kamal A, Qureshi AA. Synthesis of some substituted Di Indolyl methanes in aqueous medium at room temperature. *Tetrahedron Lett* 1963; 19: 513-520.
- Chen D, Yu L, Wang PG. Lewis acid catalysed reactions in protic media, Lanthanides-catalyzed reaction of indoles with aldehydes or ketones. *Tetrahedron Lett* 1996; 37: 4467-4470.

21. Ji SJ, Zhou MF, Gu DG, Wang SY, Loh TP. Efficient synthesis of Bis(indolyl)methanes catalysed by Lewis acids in ionic liquids. *Synlett* 2003; 13: 2077-2079.
22. ME XL, Luo SZ, He JK, Cheng JP. Simple and efficient method for synthesis of Bis(indolyl)methanes with Cu(BF₄).SiO₂ Under mild conditions. *Tetrahedron Lett* 2004; 45: 4567-4570.
23. Yadav JS, Reddy BVS, Sunitha S, Reddy KS. Novel use of selectfluorTM for the synthesis of cis-fused pyrano- and furano-tetrahydro quinoline. *Adv Synth Catal* 2003; 345-349.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 1983; 65: 55-63.

Cite this article as:

Sasikala Maadwar *et al.* A facile and an efficient synthesis of 3, 3-disubstituted oxindole scaffolds and their cytotoxic properties. *Int. Res. J. Pharm.* 2019;10(4):190-195 <http://dx.doi.org/10.7897/2230-8407.1004148>

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IRJP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IRJP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IRJP editor or editorial board members.